Cargando…
Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system
High-grade serous ovarian carcinoma (HGSOC) is a genomically unstable malignancy responsible for over 70% of all deaths due to ovarian cancer. With roughly 50% of all HGSOC harboring defects in the homologous recombination (HR) DNA repair pathway (e.g., BRCA1/2 mutations), the introduction of poly A...
Autores principales: | Bound, Nirashaa T., Vandenberg, Cassandra J., Kartikasari, Apriliana E. R., Plebanski, Magdalena, Scott, Clare L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505691/ https://www.ncbi.nlm.nih.gov/pubmed/36159999 http://dx.doi.org/10.3389/fgene.2022.886170 |
Ejemplares similares
-
Regulatory T Cells in Ovarian Carcinogenesis and Future Therapeutic Opportunities
por: Cassar, Emily, et al.
Publicado: (2022) -
Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis
por: Amer, Hina, et al.
Publicado: (2021) -
Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses
por: Kampan, Nirmala Chandralega, et al.
Publicado: (2023) -
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018) -
Potential Impact of Human Cytomegalovirus Infection on Immunity to Ovarian Tumours and Cancer Progression
por: Cox, Momodou, et al.
Publicado: (2021)